



WELTRUZA (Olanzapine LAI) U.S. FDA Approval, A New Growth Chapter for Medincell

October 9, 2026

IMPORTANT NOTICE - YOU MUST READ THE FOLLOWING BEFORE CONTINUING

This presentation and the related conference call contain forward-looking statements, including statements regarding the Company's expectations concerning: (i) the timing, progress and outcome of its clinical trials; (ii) the clinical benefits and competitive positioning of its product candidates; (iii) the ability of its products to obtain regulatory approvals, commence commercial production and achieve market penetration and sales; (iv) its future product portfolio; (v) its future partnering arrangements; (vi) its future capital needs, capital expenditure plans and ability to obtain funding; and (vii) prospective financial matters regarding its business.

Although the Company believes that its expectations are based on reasonable assumptions, any statements other than statements of historical fact contained in this presentation or made during the related conference call regarding future events are forward-looking statements and are subject to change without notice due to factors beyond the Company's control and the Company's financial capabilities.

These statements may include, but are not limited to, statements beginning with, followed by or including words or phrases such as "objective," "believe," "anticipate," "expect," "foresee," "aim," "intend," "may," "estimate," "plan," "project," "will," "probably," "potential," "should," "could" and other words or phrases of similar meaning or used in the negative form.

Forward-looking statements are subject to inherent risks and uncertainties beyond the Company's control that may cause actual results, performance or achievements to differ materially from those anticipated or expressed, explicitly or implicitly, in such forward-looking statements. A list and description of these risks, contingencies and uncertainties can be found in the documents filed by the Company with the Autorité des marchés financiers, or "AMF," pursuant to its regulatory obligations, including the Company's 2025/2026 Universal Registration Document filed with the AMF on July 27, 2026, as well as in documents and reports subsequently published by the Company.

Readers are cautioned not to place undue reliance on these forward-looking statements. Except as required by applicable law, the Company does not undertake any obligation to publicly update or revise any forward-looking statement, including to reflect new information, future events or circumstances. Any update by the Company of one or more forward-looking statements does not imply that the Company will make any further updates to such forward-looking statements or to any other forward-looking statements.

This presentation and the related conference call are provided for information purposes only. The information contained herein does not constitute an offer to sell or a solicitation of an offer to buy or subscribe for the Company's shares in any jurisdiction, in particular in France. Similarly, this presentation does not constitute investment advice and should not be treated as such. It does not take into account the investment objectives, financial situation or specific needs of any recipient and should not deprive recipients of the opportunity to exercise their own judgment.

All opinions expressed in this document are subject to change without notice. The distribution of this presentation may be subject to legal restrictions in certain jurisdictions. Persons who become aware of this presentation are encouraged to inform themselves about, and are required to comply with, such restrictions.

All information contained in this presentation and provided during the related conference call speaks only as of: (i) the date hereof, in the case of information concerning the Company; and (ii) the date of such information, in the case of information provided by persons other than the Company. The Company does not undertake any duty to update or revise the information contained herein, publicly or otherwise.

The Company has not independently verified any third-party information contained in this presentation and makes no representation as to the accuracy or completeness of such information.

UZEDY® and WELTRUZA™ are registered trademarks of Teva Pharmaceuticals.

“Shift to Growth” Strategy

3 Engines Firing in Parallel

ABBVIE #1, PIPELINE & INNOVATION

03

OLANZAPINE LAI



WELTRUZA is a registered trademark of Teva Pharmaceuticals USA, Inc.

RISPERIDONE LAI

01



WELTRUZA™ : Transformational Milestone for MedinCell

Innovation impact



**First & only subcutaneous
once-monthly olanzapine
LAI for the treatment of
schizophrenia in adults**

Financial impact



**A new long-term
revenue stream**

Platform validation



**A second FDA-
approved product**

A Severe Disease Burden

A Persistent Adherence Challenge

Schizophrenia is a chronic, progressive and debilitating disorder

~1%
of the global
population

20–29
peak age
of onset

25–35%
of psychiatric
hospitalizations

~28.5 years
of average life lost

**67% of schizophrenia patients are non-adherent
or off treatment at 12 months¹**

Addressing the Adherence Challenge


Missed doses can lead to negative treatment response and relapse¹

Preventing relapse helps preserve long-term stability²

Improved adherence with LAIs is associated with lower relapse risk²

LAIs are at the core of schizophrenia innovation


Strong Dynamics of LAI Penetration in Schizophrenia



LAI penetration in total treated schizophrenia population, in %

Source: LAI penetration based on IQVIA sales in Month of Therapy volume, with MIDAS (sales) dataset for EU and NDA Trx dataset for US / Teva's Innovation Strategy Day, May 2025

~300,000 U.S. Patients on Oral Olanzapine, the Initial Addressable Opportunity



Olanzapine is the most prescribed atypical oral antipsychotic in schizophrenia

Established treatment option, including in more complex patient populations

Minimal penetration of existing LAI due to post-injection monitoring requirement

Teva Pharmaceuticals, Q2 2026 Results, July 29, 2026: 1. DRG / Clarivate (Nov 2025 Market Forecast Assumptions-Schizophrenia); 2. Schizophrenia patients and LAAD Rx (LAI & Oral) claims from LAAD April 2026 data file for FY2025 with 2-year look-back

**WELTRUZA[™] is the first Olanzapine LAI
approved in the U.S. without a post-injection
monitoring requirement**

WELTRUZA™ is the First and Only Once-Monthly Subcutaneous Olanzapine LAI

Convenient, differentiated administration

- Once-monthly subcutaneous long-acting injectable
- No loading doses and no oral supplementation at initiation
- Available in three once-monthly doses¹



Demonstrated efficacy in Phase 3 SOLARIS²

- Improvement in symptoms (PANSS)
- Significant reduction in illness severity (CGI-S)
- Improved personal & social functioning (PSP)

Well-characterized safety profile²

- No PDSS during clinical Phase 3 (~3,900 injections)
- Systemic safety profile consistent with oral olanzapine

1. 318 mg, 425 mg and 531 mg corresponding to oral olanzapine doses of 10 mg, 15 mg and 20 mg daily, respectively; 2.Data on file. Clinical Study Report. November 2025. Parsippany, NJ: Teva Neuroscience, Inc.

Two Complementary LAIs Across the Care Pathway




**A broad share of U.S. schizophrenia patients
now addressable**

A Major Untapped Antipsychotic LAI Opportunity

Risperidone*

~1/3 of treated patients on LAI




Oral: ~280,000 patients

LAI: ~140,000 patients

* Risperidone and its metabolite paliperidone

Olanzapine

Minimal LAI penetration to date



Oral: ~300,000 patients

LAI: <200 patients

Charts represent estimated patient shares in the U.S., not market value.

The risperidone precedent is provided for illustrative purposes only and is not indicative of expected adoption for WELTRUZA™

WELTRUZA™ Will Benefit from Teva's Proven Commercial Expertise

**Schizophrenia
market expertise**

**Established
commercial
infrastructure**

**UZEDY® successful
launch experience**

Differentiated product + Commercial execution

One Economic Model, Two Products

	UZEDY®	WELTRUZA™
Royalties	Mid- to high-single digit on all net sales	Mid- to high-single digit on all net sales
Remaining milestones	Up to \$108 million, including \$105m of commercial milestones	Up to \$112m, including \$4m upon US approval and \$105m of commercial milestones

Commercial milestones will be paid in multiple installments as annual net sales reach specified thresholds for each product and may not be achieved. Royalty thresholds and applicable rates are assessed separately for each product..

U.S. Patent Portfolio

**Latest listed
patent expiration**

2044

*Dates reflect currently listed U.S. patent expirations and may be subject to applicable adjustments, extensions and other factors.

WELTRUZA™ Opens a New Growth Chapter for Medincell



Addresses a major treatment gap and unlocks a significant market opportunity



Creates a second long-term royalty stream



Establishes Medincell's platform as a proven engine for differentiated long-acting medicines

The most transformative years in Medincell's History